13F Holdings
中文EN

STRO SUTRO BIOPHARMA, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%

Returns

ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.10M$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M
R&D expense$23.50M$31.70M$36.55M$36.64M$39.85M$38.33M$51.60M$71.04M
SG&A expense$7.54M$7.83M$7.58M$8.66M$8.74M$10.34M$13.27M$9.03M
Operating income-$21.96M-$29.89M-$29.66M-$38.05M-$48.46M-$3.35M-$68.51M-$65.26M
Pretax income-$31.49M-$38.53M-$38.50M-$46.84M-$56.86M-$11.52M-$75.96M-$70.09M
Income tax$0$1,000-$15,000-$82,000$0-$18,000$7,000$2.35M
Net income-$31.49M-$38.53M-$38.48M-$46.76M-$56.86M-$11.50M-$75.97M-$72.44M
EBITDA-$20.71M-$28.63M-$28.38M-$36.42M-$46.56M-$1.45M-$66.61M-$63.39M
EPS (basic)-1.90-2.33-2.94—-6.66-1.35-9.08—
EPS (diluted)-1.90-2.33-2.94—-6.66-1.35-9.08—
Weighted avg. shares (diluted)16.58M16.57M13.08M—8.54M8.51M8.36M—
Balance sheet
Cash & equivalents$46.85M$54.34M$73.68M$58.13M$65.93M$64.03M$106.23M$190.30M
Short-term investments$95.33M$110.01M$128.88M$83.30M$101.67M$141.11M$142.74M$126.59M
Receivables$12.81M$5.80M$12.48M$3.98M$3.92M$8.00M$13.56M$8.62M
Current assets$159.50M$175.65M$220.97M$150.93M$182.11M$231.63M$287.41M$343.31M
PP&E, net$7.13M$8.36M$9.36M$10.65M$13.35M$14.98M$16.80M$18.19M
Total assets$176.65M$194.46M$241.99M$173.83M$209.66M$262.36M$321.43M$387.21M
Current liabilities$54.31M$52.90M$70.81M$75.13M$71.89M$74.25M$133.05M$131.89M
Total liabilities$309.18M$297.78M$308.88M$306.28M$296.93M$294.47M$347.24M$342.61M
Shareholders' equity-$132.54M-$103.32M-$66.89M-$132.45M-$87.27M-$32.11M-$25.81M$44.60M
Shares outstanding16.60M16.58M16.57M8.58M85.10M84.72M84.35M8.31M
Cash flow statement
Operating cash flow-$22.45M-$38.29M-$42.26M-$26.43M-$38.19M-$44.72M-$67.88M-$71.74M
Investing cash flow$14.83M$19.36M-$45.26M$18.70M$39.99M$2.58M-$16.26M$87.49M
Financing cash flow$133,000-$418,000$103.08M-$64,000$102,000-$60,000$66,000-$24,000
Depreciation & amortization$1.24M$1.26M$1.28M$1.62M$1.90M$1.90M$1.90M$1.87M
Stock-based compensation$2.16M$2.01M$1.56M$1.66M$1.55M$5.26M$5.54M$5.92M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.